๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

High prevalence of the His63Asp HFE mutation in italian patients with porphyria cutanea tarda

โœ Scribed by Maurizio Sampietro; Alberto Piperno; Loredana Lupica; Cristina Arosio; Anna Vergani; Noemi Corbetta; Ida Malosio; Michela Mattioli; Anna Ludovica Fracanzani; Maria Domenica Cappellini; Gemino Fiorelli; Silvia Fargion


Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
67 KB
Volume
27
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

โœฆ Synopsis


Sporadic porphyria cutanea tarda (PCT) is caused by a reduced activity of uroporphyrinogen decarboxylase (URO-D) in the liver. Mild to moderate iron overload is common in PCT, as iron is one of the factors which trigger the clinical manifestations of the disease through the inactivation of URO-D. A role for genetic hemochromatosis in the development of iron overload in sporadic PCT has been hypothesized in the past. The aim of this work was to investigate whether mutations of HFE, which is a candidate gene for hemochromatosis, play the role of genetic susceptibility factors for PCT in Italian patients, who have a high prevalence of acquired triggering factors, such as hepatitis C virus (HCV) chronic infection and alcohol. We determined HFE genotypes of 68 male patients with PCT. Our data do not confirm an association of PCT with the Cys282Tyr HFE mutation, strongly associated with hemochromatosis in Northern European countries. A second mutation of HFE, His63Asp, however, had a significantly increased frequency as it was present in half of the patients. Surprisingly, the presence of the His63Asp mutation was not related to the iron status of patients, suggesting that a subtle abnormality of iron metabolism induced by this mutation could escape detection by the standard parameters of iron status. In PCT patients with liver disease, the presence of the mutation could contribute to the inactivation of URO-D, either directly or through a synergistic action with other factors that cause liver damage. (HEPATOLOGY 1998;27;181-184.)

Sporadic porphyria cutanea tarda (PCT), the most common type of porphyria, 1 is caused by a reduced activity of Abbreviations: PCT, porphyria cutanea tarda; URO-D, uroporphyrinogen decarboxylase; HLA, human leukocyte antigen; HCV, hepatitis C virus.


๐Ÿ“œ SIMILAR VOLUMES


The most frequent HFE allele linked to p
โœ Rafael Enriquez de Salamanca; Pablo Morales; M. Jose Castro; Ricardo Rojo; Mario ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 56 KB ๐Ÿ‘ 1 views

Porphyria cutanea tarda (PCT) is caused by reduced activity of uroporphyrinogen decarboxylase (URO-D) in the liver, yielding hepatic accumulation of uroporphyrins and photosensitive skin lesions. Excess hepatic iron, together with inappropriately high iron absorption, also occurs in PCT. A new major

Extremely rare association of HFE mutati
โœ Kazumichi Furuyama; Masao Kondo; Kenji Hirata; Hiroyoshi Fujita; Shigeru Sassa ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 48 KB ๐Ÿ‘ 1 views

et al. 6 who also found no association between the C282Y mutation and SPCT. The H63D mutation was observed in 10 of the 48 PCT patients corresponding to 20.8%. Of the 10 individuals diagnosed, 4 belonged to the familial form of PCT and 6 to the sporadic form. The mutations detected were all heteroz

C282Y and H63D mutations in the HFE gene
โœ Aneta Ivanova; Nicolas von Ahsen; Dimtcho Adjarov; Zahari Krastev; Michael Oelle ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 54 KB ๐Ÿ‘ 2 views

Viral genotyping was performed in 61 patients with untreated chronic hepatitis C using the Inno-Lipa HCV II assay (Innogenetics, Zwijnaarde, Belgium). Steatosis was graded as previously reported. 1 The association between viral genotype and steatosis was tested using the Pearson' s 2 statistic and t

High prevalence of the JAK2 V617F mutati
โœ Valerio De Stefano; Alessia Fiorini; Elena Rossi; Tommaso Za; Patrizia Chiusolo; ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 56 KB

We read with interest the special article byShneider et al. 1 , which was published in November 2006, but related to a conference held in March 2006. As regards hepatitis B, Shneider et al. state: "Unfortunately at present there are inadequate numbers of patients with sufficiently long follow-up to